이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Unichem Laboratories 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Pabitrakumar Bhattacharyya

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	6.1yrs
이사회 평균 재임 기간	1.1yrs

최근 관리 업데이트

Recent updates

CEO

Pabitrakumar Bhattacharyya (55 yo)

less than a year

테뉴어

Mr. Pabitrakumar Kalipada Bhattacharyya serves as a Managing Director and Director at Unichem Laboratories Limited since August 10, 2023. Mr. Bhattacharyya brings rich experience from organizations like Su...

리더십 팀

이름	위치	테뉴어	보상	소유권
Sandip Ghume	Deputy Chief Financial Officer	no data	₹10.75m	데이터 없음
Pradeep Bhandari	Head of Legal & Company Secretary	4.9yrs	₹9.66m	데이터 없음
Pabitrakumar Bhattacharyya	MD & Director	less than a year	데이터 없음	데이터 없음
Jalesh Burye	Chief Quality & Compliance Officer	no data	데이터 없음	데이터 없음
Prasad Joshi	Vice President of Human Resources & ER	16.1yrs	₹7.48m	데이터 없음
Vinod Behl	Head of Projects & Investments	no data	₹2.10m	데이터 없음
Dhananjay Sathe	Chief Scientific & Compliance Officer	no data	데이터 없음	데이터 없음
Ashwani Kumar	Chief Manufacturing & Compliance Officer	no data	데이터 없음	데이터 없음
Bhagwat Dhingra	Chief Executive of Domestic Pharma	11.9yrs	₹13.62m	데이터 없음
Scott Delaney	President of North America & CEO of North America	6.1yrs	데이터 없음	데이터 없음
P. Deshpande	Vice President of Chemical of Research and Development	no data	₹593.35k	데이터 없음
Supriya Mody	Associate Vice President of International Business	no data	₹3.82m	1.35% ₹ 507.4m

6.1yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 관리: 506690 의 관리팀은 노련하고 경험 (평균 재직 기간 6 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Pabitrakumar Bhattacharyya	MD & Director	less than a year	데이터 없음	데이터 없음
Prakash Mody	Chairman	50.1yrs	₹59.24m	16.21% ₹ 6.1b
Arun Todarwal	Independent Director	no data	데이터 없음	데이터 없음
Pranay Godha	Non-Executive Non-Independent Director	less than a year	데이터 없음	데이터 없음
Priti Puri	Additional Independent Non-Executive Director	1.3yrs	데이터 없음	데이터 없음
Anand Kusre	Independent Director	no data	데이터 없음	데이터 없음

1.1yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 이사회: 506690 의 이사회는 경험(평균 재직 기간 1 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Unichem Laboratories 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024

Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Insider recently sold ₹1.5m worth of stock

Recent updates

Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

Unichem Laboratories Limited to Report Q4, 2024 Results on May 22, 2024

Third quarter 2024 earnings released: EPS: ₹11.93 (vs ₹9.08 loss in 3Q 2023)

Unichem Laboratories Limited to Report Q3, 2024 Results on Feb 05, 2024

Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg

Second quarter 2024 earnings released: ₹3.48 loss per share (vs ₹10.04 loss in 2Q 2023)

Unichem Laboratories Limited to Report Q2, 2024 Results on Nov 01, 2023

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Insider recently sold ₹1.5m worth of stock

First quarter 2024 earnings released: ₹0.09 loss per share (vs ₹3.32 loss in 1Q 2023)

Non-Executive Independent Director recently sold ₹10m worth of stock

Full year 2023 earnings released: ₹28.72 loss per share (vs ₹4.70 profit in FY 2022)

Third quarter 2023 earnings released: ₹9.08 loss per share (vs ₹2.01 loss in 3Q 2022)

Krka Reportedly Eyes Promoter Stake in Unichem Laboratories

Insufficient new directors

Second quarter 2023 earnings released: ₹10.04 loss per share (vs ₹1.82 loss in 2Q 2022)

Unichem Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Unichem Laboratories Limited Receives ANDA Approval for Extended Phenytoin Sodium Capsules USP, 100 Mg from United States Food and Drug Administration

Unichem Laboratories Limited Receives ANDA Approval for Carbamazepine Tablets USP

Unichem Laboratories Limited Receives ANDA Approval for Its Quetiapine Extended-Release Tablets

Unichem Laboratories Limited Receives ANDA Approval for its Labetalol Hydrochloride Tablets, USP 100 Mg, 200 Mg, and 300 Mg from the United States Food and Drug Administration

Unichem Laboratories Limited to Report Q1, 2023 Results on Aug 09, 2022

Upcoming dividend of ₹4.00 per share

Full year 2022 earnings released: EPS: ₹4.70 (vs ₹4.88 in FY 2021)

Unichem Laboratories Limited, Annual General Meeting, Aug 09, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Unichem Laboratories Limited Recommends Final Dividend for the Year Ended March 31, 2022

Unichem Laboratories Limited to Report Q4, 2022 Results on May 27, 2022

Insufficient new directors

Unichem Laboratories Limited Receives ANDA Approval for Its Divalproex Sodium Extended-Release Tablet

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings released: ₹1.82 loss per share (vs ₹1.24 profit in 2Q 2021)

Upcoming dividend of ₹4.00 per share

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Receives Tentative USFDA Approval for ANDA of Aripiprazole Tablets

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Recommends Dividend for the Year Ended March 31, 2021

Unichem Laboratories Limited Announces That It Has Received ANDA Approval for its Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg

Insider recently bought ₹2.3m worth of stock

Unichem Laboratories Limited Receives ANDA Approval for Its Guanfacine Tablets, USP 1 Mg and 2 Mg from the United States Food and Drug Administration

New 90-day high: ₹332

Unichem Laboratories Limited Receives Anda Approval for Its Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg from the United States Food and Drug Administration

New 90-day high: ₹294

Third quarter 2021 earnings released: EPS ₹3.35 (vs ₹2.07 loss in 3Q 2020)

Unichem Laboratories Limited Receives ANDA Approval for its Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg from USFDA

Unichem Laboratories Limited to Report Q3, 2021 Results on Jan 30, 2021

New 90-day high: ₹286

Unichem Laboratories Limited Receives ANDA Approval from USFDA for Unichem's Celecoxib Capsules, 50 Mg, 100 Mg, 200 Mg, and 400 Mg

New 90-day high: ₹285

Unichem Laboratories Limited Receives ANDA Approval for Atenolol and Chlorthalidone Tablet

New 90-day low: ₹237

Second quarter 2021 earnings released: EPS ₹1.24

First half earnings released

Upcoming Dividend of ₹4.00 Per Share

First quarter earnings released

New 90-day high - ₹214

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령